Medication evidence profile
Alimemazine
Clinical overview
Alimemazine has public medication-list entries in JARS 2025, Swe-ABS 2023, KABS 2020 open validation supplement, and CALS 2022 Table 4. These are 4 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | 2 |
| Yamada-ABS | Not listed |
| BAAS | Not listed |
| Swe-ABS | 2 |
| GABS | Not listed |
| KABS | 1 |
| CALS | 1 |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
Other names used in the sources
Alimemazine (trimeprazine)
How to interpret the evidence
4 of 7 public source versions contain an explicit medication-list entry for Alimemazine.
The recorded values differ across the source rows for Alimemazine. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 4 observations
- Japanese Anticholinergic Risk Scale (JARS) 2025 English translation
Source label: Alimemazine. Published value: 2.
Source version: JARS-2025
Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=R06AD01
Observation: JARS_2025_R0137; rating state: published_rating. - Swedish Anticholinergic Burden Scale 2023
Source label: Alimemazine. Published value: 2.
Source version: SWE-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_final_nonzero_complete
Observation: SWE_ABS_2023_R0066; rating state: published_rating. - KABS 2019 scale - 2020 open validation supplement
Source label: Trimeprazine;Alimemazine. Published value: 1.
Source version: KABS-2020-validation-supplement
Source location: Additional file 1; category Antihistamines; table row 23
Observation: KABS2020_SUPP_0079; rating state: published_validation_supplement_rating. - CALS 2022 - primary final Table 4
Source label: Alimemazine. Published value: 1.
Source version: CALS-2022-primary-table4
Source location: Table 4; literal capture row 8; displayed table row 2; displayed column 1
Observation: CALS2022_T4_0008; rating state: published_final_table_rating.
What this page does not establish
- No medication-list entry is available here from Yamada-ABS 2023, BAAS 2019, and GABS 2018. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- Do not infer route equivalence from canonical grouping; use source label/table annotations.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Suh Y, Ah YM, Han E, et al. Dose response relationship of cumulative anticholinergic exposure with incident dementia: validation study of Korean anticholinergic burden scale. BMC Geriatr. 2020;20(1):265. doi:10.1186/s12877-020-01671-z. Open source
- Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Alimemazine
Ask about this medication